1
|
Heusser K, Tank J, Diedrich A, Fischer A, Heise T, Jordan J. Limited evidence for sympathetic neural overactivation in older patients with type 2 diabetes mellitus. Front Neurosci 2023; 16:1107752. [PMID: 36711125 PMCID: PMC9878600 DOI: 10.3389/fnins.2022.1107752] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/25/2022] [Accepted: 12/30/2022] [Indexed: 01/13/2023] Open
Abstract
Introduction Mechanistic studies suggested that excess sympathetic activity promotes arterial hypertension while worsening insulin sensitivity. Older patients with type 2 diabetes are at particularly high cardiovascular and metabolic risk. However, data on sympathetic activity in this population is scarce. Methods We studied 61 patients with type 2 diabetes mellitus (22 women, 60.9 ± 1.4 years; 39 men, 60.9 ± 1.4 years). They had to have diabetes for at least 2 years, a hemoglobin A1c of 6.5-10%, a body-mass-index of 20-40 kg/m2, and had to be treated with stable doses of metformin only. We recorded ECG, finger and brachial blood pressure, and muscle sympathetic nerve activity (MSNA). Results MSNA was 37.5 ± 2.5 bursts/min in women and 39.0 ± 2.0 bursts/min in men (p = 0.55). MSNA expressed as burst incidence was 52.7 ± 2.0 bursts/100 beats in women and 59.2 ± 3.1 bursts/100 beats in men (p = 0.21). Five out of 39 men (12.8%) and two out of 22 women (9.1%) exhibited resting MSNA measurements above the 95th percentile for sex and age. In the pooled analysis, MSNA was not significantly correlated with systolic blood pressure, diastolic blood pressure, body mass index, waist circumference, body composition, or HbA1c (r 2 < 0.02, p > 0.26 for all). Discussion We conclude that relatively few older patients with type 2 diabetes mellitus exhibit increased MSNA. The large interindividual variability in MSNA cannot be explained by gender, blood pressure, body mass index, or glycemic control.
Collapse
Affiliation(s)
- Karsten Heusser
- Institute of Aerospace Medicine, German Aerospace Center, Cologne, Germany
| | - Jens Tank
- Institute of Aerospace Medicine, German Aerospace Center, Cologne, Germany
| | - André Diedrich
- Vanderbilt Autonomic Dysfunction Center, Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, United States,Department of Biomedical Engineering, School of Engineering, Vanderbilt University, Nashville, TN, United States
| | - Annelie Fischer
- Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany
| | - Tim Heise
- Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany
| | - Jens Jordan
- Institute of Aerospace Medicine, German Aerospace Center, Cologne, Germany,Medical Faculty, University of Cologne, Cologne, Germany,*Correspondence: Jens Jordan,
| |
Collapse
|
2
|
van Kleef MEAM, Heusser K, Diedrich A, Oey PL, Tank J, Jordan J, Blankestijn PJ, Williams B, Spiering W. Endovascular baroreflex amplification and the effect on sympathetic nerve activity in patients with resistant hypertension: A proof-of-principle study. PLoS One 2021; 16:e0259826. [PMID: 34784359 PMCID: PMC8594823 DOI: 10.1371/journal.pone.0259826] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2021] [Accepted: 06/21/2021] [Indexed: 11/19/2022] Open
Abstract
BACKGROUND First in human studies suggest that endovascular baroreflex amplification (EVBA) lowers blood pressure (BP). To explore potential mechanisms for BP reduction, this study examines the effects of EVBA on muscle sympathetic nerve activity (MSNA) and baroreceptor sensitivity (BRS). METHODS In a single-center sub-study of the CALM-DIEM study (Controlling And Lowering blood pressure with the MobiusHD-Defining Efficacy Markers), 14 patients with resistant hypertension were treated with EVBA. Microneurography and non-invasive continuous BP measurements were performed at baseline and three months after MobiusHD implantation. The primary outcome was change in MSNA. Secondary outcomes were change in baroreflex sensitivity (BRS), cardiovascular responses to a sympathetic stimulus, BP, heart rate (HR) and heart rate variability (HRV). RESULTS The primary endpoint was obtained in 10 of 14 patients enrolled in the sub-study. MSNA burst frequency and burst incidence decreased in 6 of 10 patients: mean change -4.1 bursts/min (95% confidence interval -12.2 to 4.0) and -3.8 bursts/100 heartbeats (-15.2 to 7.7). MSNA spike frequency and spike count decreased in 8 of 10 patients: mean change -2.8 spikes/sec (-7.3 to 1.8) and -3.0 spikes/heartbeat (-6.1 to 0.1). Change in MSNA and BP were not correlated. Office BP decreased by -14/-6 mmHg (-27 to -2/-15 to 3). We observed a trend towards decreased HR (-5 bpm, -10 to 1) and increased total power HRV (623 msec2, 78 to 1168). In contrast, BRS and cardiovascular responses remained unchanged after EVBA. CONCLUSIONS In this proof-of-principle study, EVBA did not significantly decrease MSNA in patients with resistant hypertension. EVBA did not impair baroreflex function. TRIAL REGISTRATION Clinical trial registration at NCT02827032.
Collapse
Affiliation(s)
| | - Karsten Heusser
- Institute of Aerospace Medicine, German Aerospace Center, Cologne, Germany
| | - André Diedrich
- Division of Clinical Pharmacology, Department of Medicine, Autonomic Dysfunction Center, Vanderbilt University Medical Center, Nashville, TN, United States of America
| | - P. Liam Oey
- Department of Nephrology, University Medical Center Utrecht, Utrecht, The Netherlands
| | - Jens Tank
- Institute of Aerospace Medicine, German Aerospace Center, Cologne, Germany
| | - Jens Jordan
- Institute of Aerospace Medicine, German Aerospace Center, Cologne, Germany
| | - Peter J. Blankestijn
- Department of Nephrology, University Medical Center Utrecht, Utrecht, The Netherlands
| | - Bryan Williams
- University College London (UCL) Institute of Cardiovascular Science and National Institute for Health Research (NIHR) UCL Hospitals Biomedical Research Centre, London, United Kingdom
| | - Wilko Spiering
- Department of Vascular Medicine, University Medical Center Utrecht, Utrecht, The Netherlands
- * E-mail:
| |
Collapse
|
8
|
Heusser K, Tank J, Brinkmann J, Menne J, Kaufeld J, Linnenweber-Held S, Beige J, Wilhelmi M, Diedrich A, Haller H, Jordan J. Acute Response to Unilateral Unipolar Electrical Carotid Sinus Stimulation in Patients With Resistant Arterial Hypertension. Hypertension 2016; 67:585-91. [PMID: 26831195 DOI: 10.1161/hypertensionaha.115.06486] [Citation(s) in RCA: 52] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2015] [Accepted: 01/06/2016] [Indexed: 01/14/2023]
Abstract
Bilateral bipolar electric carotid sinus stimulation acutely reduced muscle sympathetic nerve activity (MSNA) and blood pressure (BP) in patients with resistant arterial hypertension but is no longer available. The second-generation device uses a smaller unilateral unipolar disk electrode to reduce invasiveness while saving battery life. We hypothesized that the second-generation device acutely lowers BP and MSNA in treatment-resistant hypertensive patients. Eighteen treatment-resistant hypertensive patients (9 women/9 men; 53±11 years; 33±5 kg/m(2)) on stable medications have been included in the study. We monitored finger and brachial BP, heart rate, and MSNA. Without stimulation, BP was 165±31/91±18 mm Hg, heart rate was 75±17 bpm, and MSNA was 48±14 bursts per minute. Acute stimulation with intensities producing side effects that were tolerable in the short term elicited interindividually variable changes in systolic BP (-16.9±15.0 mm Hg; range, 0.0 to -40.8 mm Hg; P=0.002), heart rate (-3.6±3.6 bpm; P=0.004), and MSNA (-2.0±5.8 bursts per minute; P=0.375). Stimulation intensities had to be lowered in 12 patients to avoid side effects at the expense of efficacy (systolic BP, -6.3±7.0 mm Hg; range, 2.8 to -14.5 mm Hg; P=0.028 and heart rate, -1.5±2.3 bpm; P=0.078; comparison against responses with side effects). Reductions in diastolic BP and MSNA (total activity) were correlated (r(2)=0.329; P=0.025). In our patient cohort, unilateral unipolar electric baroreflex stimulation acutely lowered BP. However, side effects may limit efficacy. The approach should be tested in a controlled comparative study.
Collapse
Affiliation(s)
- Karsten Heusser
- From the Institute of Clinical Pharmacology (K.H., J.T., J.B., J.J.), Clinic for Nephrology (J.M., J.K., S.L.-H., H.H.), Division for Cardiothoracic, Transplantation- and Vascular Surgery (M.W.), Hannover Medical School, Hannover, Germany; Department of Nephrology and KfH Renal Unit, Hospital St. Georg, Leipzig, Germany (J.B.); and Division of Clinical Pharmacology, Department of Medicine, Autonomic Dysfunction Service, Vanderbilt University, Nashville, TN (A.D.)
| | - Jens Tank
- From the Institute of Clinical Pharmacology (K.H., J.T., J.B., J.J.), Clinic for Nephrology (J.M., J.K., S.L.-H., H.H.), Division for Cardiothoracic, Transplantation- and Vascular Surgery (M.W.), Hannover Medical School, Hannover, Germany; Department of Nephrology and KfH Renal Unit, Hospital St. Georg, Leipzig, Germany (J.B.); and Division of Clinical Pharmacology, Department of Medicine, Autonomic Dysfunction Service, Vanderbilt University, Nashville, TN (A.D.)
| | - Julia Brinkmann
- From the Institute of Clinical Pharmacology (K.H., J.T., J.B., J.J.), Clinic for Nephrology (J.M., J.K., S.L.-H., H.H.), Division for Cardiothoracic, Transplantation- and Vascular Surgery (M.W.), Hannover Medical School, Hannover, Germany; Department of Nephrology and KfH Renal Unit, Hospital St. Georg, Leipzig, Germany (J.B.); and Division of Clinical Pharmacology, Department of Medicine, Autonomic Dysfunction Service, Vanderbilt University, Nashville, TN (A.D.)
| | - Jan Menne
- From the Institute of Clinical Pharmacology (K.H., J.T., J.B., J.J.), Clinic for Nephrology (J.M., J.K., S.L.-H., H.H.), Division for Cardiothoracic, Transplantation- and Vascular Surgery (M.W.), Hannover Medical School, Hannover, Germany; Department of Nephrology and KfH Renal Unit, Hospital St. Georg, Leipzig, Germany (J.B.); and Division of Clinical Pharmacology, Department of Medicine, Autonomic Dysfunction Service, Vanderbilt University, Nashville, TN (A.D.)
| | - Jessica Kaufeld
- From the Institute of Clinical Pharmacology (K.H., J.T., J.B., J.J.), Clinic for Nephrology (J.M., J.K., S.L.-H., H.H.), Division for Cardiothoracic, Transplantation- and Vascular Surgery (M.W.), Hannover Medical School, Hannover, Germany; Department of Nephrology and KfH Renal Unit, Hospital St. Georg, Leipzig, Germany (J.B.); and Division of Clinical Pharmacology, Department of Medicine, Autonomic Dysfunction Service, Vanderbilt University, Nashville, TN (A.D.)
| | - Silvia Linnenweber-Held
- From the Institute of Clinical Pharmacology (K.H., J.T., J.B., J.J.), Clinic for Nephrology (J.M., J.K., S.L.-H., H.H.), Division for Cardiothoracic, Transplantation- and Vascular Surgery (M.W.), Hannover Medical School, Hannover, Germany; Department of Nephrology and KfH Renal Unit, Hospital St. Georg, Leipzig, Germany (J.B.); and Division of Clinical Pharmacology, Department of Medicine, Autonomic Dysfunction Service, Vanderbilt University, Nashville, TN (A.D.)
| | - Joachim Beige
- From the Institute of Clinical Pharmacology (K.H., J.T., J.B., J.J.), Clinic for Nephrology (J.M., J.K., S.L.-H., H.H.), Division for Cardiothoracic, Transplantation- and Vascular Surgery (M.W.), Hannover Medical School, Hannover, Germany; Department of Nephrology and KfH Renal Unit, Hospital St. Georg, Leipzig, Germany (J.B.); and Division of Clinical Pharmacology, Department of Medicine, Autonomic Dysfunction Service, Vanderbilt University, Nashville, TN (A.D.)
| | - Mathias Wilhelmi
- From the Institute of Clinical Pharmacology (K.H., J.T., J.B., J.J.), Clinic for Nephrology (J.M., J.K., S.L.-H., H.H.), Division for Cardiothoracic, Transplantation- and Vascular Surgery (M.W.), Hannover Medical School, Hannover, Germany; Department of Nephrology and KfH Renal Unit, Hospital St. Georg, Leipzig, Germany (J.B.); and Division of Clinical Pharmacology, Department of Medicine, Autonomic Dysfunction Service, Vanderbilt University, Nashville, TN (A.D.)
| | - André Diedrich
- From the Institute of Clinical Pharmacology (K.H., J.T., J.B., J.J.), Clinic for Nephrology (J.M., J.K., S.L.-H., H.H.), Division for Cardiothoracic, Transplantation- and Vascular Surgery (M.W.), Hannover Medical School, Hannover, Germany; Department of Nephrology and KfH Renal Unit, Hospital St. Georg, Leipzig, Germany (J.B.); and Division of Clinical Pharmacology, Department of Medicine, Autonomic Dysfunction Service, Vanderbilt University, Nashville, TN (A.D.)
| | - Hermann Haller
- From the Institute of Clinical Pharmacology (K.H., J.T., J.B., J.J.), Clinic for Nephrology (J.M., J.K., S.L.-H., H.H.), Division for Cardiothoracic, Transplantation- and Vascular Surgery (M.W.), Hannover Medical School, Hannover, Germany; Department of Nephrology and KfH Renal Unit, Hospital St. Georg, Leipzig, Germany (J.B.); and Division of Clinical Pharmacology, Department of Medicine, Autonomic Dysfunction Service, Vanderbilt University, Nashville, TN (A.D.)
| | - Jens Jordan
- From the Institute of Clinical Pharmacology (K.H., J.T., J.B., J.J.), Clinic for Nephrology (J.M., J.K., S.L.-H., H.H.), Division for Cardiothoracic, Transplantation- and Vascular Surgery (M.W.), Hannover Medical School, Hannover, Germany; Department of Nephrology and KfH Renal Unit, Hospital St. Georg, Leipzig, Germany (J.B.); and Division of Clinical Pharmacology, Department of Medicine, Autonomic Dysfunction Service, Vanderbilt University, Nashville, TN (A.D.).
| |
Collapse
|